VJHemOnc is committed to improving our service to you

SOHO 2020 | Glasdegib as maintenance therapy in AML and MDS

VJHemOnc is committed to improving our service to you

Daniel Pollyea

Daniel Pollyea, MD, MS, of the University of Colorado, Denver, CO, discusses the results of a study evaluating glasdegib, a hedgehog inhibitor, as maintenance therapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients at high-risk for post-allogeneic stem cell transplant relapse. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter